What they were paid
iTeos Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | $50,604 | $0 | $280,962 | $0 | $331,566 |
| FY2023 | $100,000 | $150,000 | $0 | $0 | $250,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: iTeos Therapeutics, Inc. DEF 14A filed April 24, 2025, accession 0000950170-25-057666, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2024iTeos Therapeutics pays directors a $40,000 cash retainer and $280,962 in equity.
Committees
FY2024 · as the proxy prints themCompensation (Chair)
The rest of the iTeos Therapeutics board
FY2024 · as the company reported each| Director | Role | FY2024 total |
|---|---|---|
| Ann D. Rhoads | Independent Director | $345,566 |
| David K. Lee | Independent Director | $320,072 |
| David L. Hallal | Chair of the Board | $442,822 |
| Jill DeSimone | Independent Director | $686,270 |
| Michel Detheux | Director | $0 |
| Robert Iannone | Independent Director | $341,264 |
| Tony Ho | Independent Director | $332,764 |
The full iTeos Therapeutics compensation record
free company briefThis page is one director within iTeos Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat